Please assess the completion status of the following clinical trial:

Trial Title: Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Patients with surgically resectable oral cavity SCC, all subsites, T1 - T4, N0 - N3~* Patients with surgically resectable oropharyngeal SCC, all subsites, T1 - T2, N0 - N1~* Patients with surgically resectable T4 oropharyngeal SCC, all subsites, N0 - N3~* Patients must be 18 years old or older~EXCLUSION CRITERIA:~* Patients with previous surgical resection, radiation, or chemotherapy will be excluded to rule out possible effects of local tissue changes secondary to previous treatment~* Patients with surgically unresectable disease at primary site or regional lymph nodes~* Patients with T1 - T2 SCC oropharynx, N2 - N3~* Patients with T3 SCC oropharynx , N0 - N3~* Any patient for whom non-surgical therapy is recommended as treatment of choice after multidisciplinary treatment evaluation~* Patients with an altered mental status or not capacitated for their medical decision making~* Patients with severe or unstable cardiac or cerebrovascular disease are excluded~  * myocardial infarction within the last 90 days~ * unstable angina or angina occurring during sexual intercourse~ * New York Heart Association Class 2 or greater heart failure in the last 6 months~ * uncontrolled arrhythmias~ * hypotension (\<90/50 mm Hg), or uncontrolled hypertension (\>170/100 mm Hg)~ * stroke within the last 6 months~ * Left ventricle outflow obstruction.~* Pregnant and nursing mothers will not be enrolled given unknown effects to offspring~* Concurrent nitrate, alpha-blocker, or cytochrome P-450 inhibitor use~* Renal Insufficiency defined as creatinine clearance less than 51.~* Creatinine clearance will be determined by the following Cockcroft-Gault Equation: (140-age) \* (Wt in kg) \* (0.85 if female) / (72 \* Cr)~* Patients with hepatic insufficiency.~* Patients currently taking a Phosphodiesterase (PDE) inhibitors for erectile dysfunction~* Patients who are immunocompromised, for reasons not directly related to patients malignancy~* Patients with significant alcohol or drug abuse~* Patients with unilateral blindness, hereditary retinal disorders, or increased risk of blindness~* Patients with unilateral deafness, history of hearing loss, hearing aid dependence, or clinically evident hearing loss

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm A - Tadalafil 10mg (Type: EXPERIMENTAL): Patients will receive 10mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
- Arm B - Tadalafil 20mg (Type: EXPERIMENTAL): Patients will receive 20mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
- Arm C - Placebo (Type: PLACEBO_COMPARATOR): Patients receive oral placebo once daily on days 1-20 in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).